UC study examines immunotherapy’s effect on COVID-19 outcomes

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

The Society for Immunotherapy of Cancer is taking nominations for the SITC Annual Awards and the Academy of Immuno-Oncology.

April 05, 2024

Vol.50 No.14

Clinical Roundup

UTSW discovers protective ‘acid wall’ formed by cancer cells

Cancer cells release a significantly more concentrated level of acid than previously known, forming an “acid wall” that could deter immune cells from attacking tumors, UT Southwestern Medical Center scientists showed in a study.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors.

March 29, 2024

Vol.50 No.13

Clinical Roundup

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

Insights into the workings of PD-1 reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

March 15, 2024

Vol.50 No.11

Drugs & Targets

FDA approves Tevimbra in advanced or metastatic esophageal squamous cell carcinoma indication

FDA has approved Tevimbra (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

March 15, 2024

Vol.50 No.11

Drugs & Targets

FDA issues final decision to withdraw approval of Pepaxto

FDA announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), which was approved for use in combination with dexamethasone to treat certain patients with multiple myeloma.

March 01, 2024

Vol.50 No.09

UC study examines immunotherapy’s effect on COVID-19 outcomes

YOU MAY BE INTERESTED IN

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

UTSW discovers protective ‘acid wall’ formed by cancer cells

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

FDA approves Tevimbra in advanced or metastatic esophageal squamous cell carcinoma indication

FDA issues final decision to withdraw approval of Pepaxto

Renew today!

Subscriber content

Login